We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know
Read MoreHide Full Article
The latest trading session saw Pfizer (PFE - Free Report) ending at $24.70, denoting a +0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.67% gain on the day. Meanwhile, the Dow experienced a rise of 0.56%, and the technology-dominated Nasdaq saw an increase of 0.87%.
Heading into today, shares of the drugmaker had lost 4.7% over the past month, outpacing the Medical sector's loss of 5.32% and the S&P 500's loss of 5.28% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to go public on April 29, 2025. The company's upcoming EPS is projected at $0.68, signifying a 17.07% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $13.99 billion, down 5.97% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.97 per share and revenue of $63.2 billion. These results would represent year-over-year changes of -4.5% and -0.67%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.42% higher within the past month. Currently, Pfizer is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is presently being traded at a Forward P/E ratio of 8.26. This denotes a discount relative to the industry's average Forward P/E of 13.71.
It's also important to note that PFE currently trades at a PEG ratio of 0.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.31 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know
The latest trading session saw Pfizer (PFE - Free Report) ending at $24.70, denoting a +0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.67% gain on the day. Meanwhile, the Dow experienced a rise of 0.56%, and the technology-dominated Nasdaq saw an increase of 0.87%.
Heading into today, shares of the drugmaker had lost 4.7% over the past month, outpacing the Medical sector's loss of 5.32% and the S&P 500's loss of 5.28% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to go public on April 29, 2025. The company's upcoming EPS is projected at $0.68, signifying a 17.07% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $13.99 billion, down 5.97% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.97 per share and revenue of $63.2 billion. These results would represent year-over-year changes of -4.5% and -0.67%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.42% higher within the past month. Currently, Pfizer is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is presently being traded at a Forward P/E ratio of 8.26. This denotes a discount relative to the industry's average Forward P/E of 13.71.
It's also important to note that PFE currently trades at a PEG ratio of 0.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.31 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.